Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...

Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

Is there any difference in efficacy with Keytruda (pembrolizumab ... and they would mandate a study comparing the two ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.